Acceso usuarios
Objetivo: Caracterizar la expresion y funcion de aB cristalina en la lesion medular.
Material y metodo: En un modelo animal murino .mus musculus (raton) de la cepa C57/Bl6. se realizo lesion medular mediante contusion, y los segmentos medulares fueron extraidos a los 1, 3, 7, 14, 21 y 28 dias postlesion.
Se valoraron los niveles de ARNm de aB cristalina. Asimismo, se administro aB cristalina recombinante humana tras la lesion medular y se valoro su efecto sobre la recuperacion funcional.
Resultados: Los niveles de expresion de aB cristalina no se incrementan hasta los 21 dias post-lesion. La administracion de dicha proteina promueve recuperacion funcional tras la lesion medular.
Conclusion: La administracion de aB cristalina podria ser una nueva terapia para tratar las lesiones agudas de la medula espinal
Objective: Characterize the expression and role of áB crystallin in spinal cord injury Material and method: In a murine animal model (mus musculus (C57/Bl6 mouse) spinal cord injury was induced by contusion and the spinal cord segment corresponding to the injury site was extracted at day 1, 3, 7, 14, 21, 28 post-injury and áB crystallin mRNA levels were assessed. In addition, the effects of the administration of the human áB crystallin recombinant protein after spinal cord injury was evaluated.
Results: áB crystallin mRNA levels did not increase until day 21 following spinal cord injury. Administration of áB crystallin resulted in increased functional recovery after lesion.
Conclusion: Administration of áB crystallin could therefore be valuable for the treatment of acute spinal cord injury
